167 related articles for article (PubMed ID: 17885736)
1. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.
Chen J; Lu Q; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):829-47. PubMed ID: 17885736
[TBL] [Abstract][Full Text] [Related]
2. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
Shah DK; Balthasar JP
Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
[TBL] [Abstract][Full Text] [Related]
3. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
4. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB
Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
6. Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?
Mustafa S; Venkatesh P; Pasha K; Mullangi R; Srinivas NR
Xenobiotica; 2006 Dec; 36(12):1239-58. PubMed ID: 17162470
[TBL] [Abstract][Full Text] [Related]
7. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines.
Zamboni WC; Houghton PJ; Hulstein JL; Kirstein M; Walsh J; Cheshire PJ; Hanna SK; Danks MK; Stewart CF
Cancer Chemother Pharmacol; 1999; 43(4):269-76. PubMed ID: 10071976
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma.
Chen J; Balthasar JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):183-92. PubMed ID: 15664349
[TBL] [Abstract][Full Text] [Related]
9. Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations.
Segura C; Bandrés E; Trocóniz IF; García-Foncillas J; Sayar O; Dios-Vieítez C; Renedo MJ; Garrido MJ
Pharm Res; 2004 Apr; 21(4):567-73. PubMed ID: 15139512
[TBL] [Abstract][Full Text] [Related]
10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
11. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
[TBL] [Abstract][Full Text] [Related]
12. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
Su Y; Hu P; Lee SH; Sinko PJ
J Pharm Pharm Sci; 2007; 10(4):519-36. PubMed ID: 18261372
[TBL] [Abstract][Full Text] [Related]
13. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850).
Kimura T; Okada K; Morohashi Y; Kato Y; Mori M; Kato H; Matsumoto T; Shimoyama S
Pharm Res; 2024 Apr; 41(4):795-806. PubMed ID: 38536615
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic model for topotecan in mice.
Shah DK; Balthasar JP
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):121-42. PubMed ID: 21104004
[TBL] [Abstract][Full Text] [Related]
17. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
18. An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.
Jyoti A; Fugit KD; Sethi P; McGarry RC; Anderson BD; Upreti M
Sci Rep; 2015 Oct; 5():15236. PubMed ID: 26468877
[TBL] [Abstract][Full Text] [Related]
19. The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.
Zamboni WC; Lüftner DI; Egorin MJ; Schweigert M; Sezer O; Richter T; Natale JJ; Possinger K
Ann Oncol; 2001 Jan; 12(1):119-22. PubMed ID: 11249038
[TBL] [Abstract][Full Text] [Related]
20. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.
Serwer LP; Noble CO; Michaud K; Drummond DC; Kirpotin DB; Ozawa T; Prados MD; Park JW; James CD
Neuro Oncol; 2011 Dec; 13(12):1288-95. PubMed ID: 21954443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
